Improvement in liver histology with obeticholic acid in patients with nonalcoholic steatohepatitis and type 2 diabetes

被引：0
|
作者：
Liberman, A. [1 ]
McCullough, A. [2 ]
Neuschwander-Tetri, B. [3 ]
Sanyal, A. [4 ]
Abdelmalek, M. [5 ]
Gogineni, R. [1 ]
Ferguson, B. [1 ]
Shringarpure, R. [1 ]
Shapiro, D. [1 ]
机构：
[1] Intercept Pharmaceut Inc, San Diego, CA USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] St Louis Univ, Hlth Sci Ctr, St Louis, MO 63103 USA
[4] Virginia Commonwealth Univ, Richmond, VA 23284 USA
[5] Duke Univ, Sch Med, Durham, NC 27706 USA
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1247
引用
收藏
页码：S574 / S574
页数：1
相关论文
共 50 条
  • [1] Improvement in Liver Histology with Obeticholic Acid in Patients with Nonalcoholic Steatohepatitis and Type 2 Diabetes Mellitus
    Mccullough, Arthur
    Neuschwander-Tetri, Brent A.
    Sanyal, Arun
    Abdelmalek, Manal
    Gogineni, Ranga
    Ferguson, Beatrice
    Shringarpure, Reshma
    Shapiro, David
    DIABETES, 2017, 66 : A348 - A349
  • [2] Obeticholic acid for the treatment of nonalcoholic steatohepatitis
    Shah, Raj A.
    Kowdley, Kris, V
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 14 (05) : 311 - 321
  • [3] Effect of Obeticholic Acid on the Liver Function Tests and Lipid Panel in Patients With Nonalcoholic Steatohepatitis: Metaanalysis
    Gupta, Nancy
    Garg, Sushil Kumar
    Gupta, Rahul
    Mahajan, Sugandhi
    Sule, Sachin
    GASTROENTEROLOGY, 2016, 150 (04) : S1146 - S1147
  • [4] Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
    Albai, Oana
    Timar, Romulus
    Timar, Bogdan
    DIABETES, 2014, 63 : A392 - A393
  • [5] The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
    Younossi, Zobair M.
    Golabi, Pegah
    Price, Jillian Kallman
    Owrangi, Soroor
    Gundu-Rao, Nagashree
    Satchi, Romona
    Paik, James M.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (10) : 1999 - 2010
  • [6] IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
    Bian, Hua
    Zhu, Xiaopeng
    Xia, Mingfeng
    Yan, Hongmei
    Chang, Xinxia
    Hu, Xiqi
    Pan, Baishen
    Guo, Wei
    Li, Xiaoying
    Gao, Xin
    ENDOCRINE PRACTICE, 2020, 26 (04) : 444 - 453
  • [7] PRURITUS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA)
    Younossi, Zobair M.
    Stepanova, Maria
    Nader, Fatema
    Bonacci, Martin
    Wong, Bruce
    Loomba, Rohit
    Rinella, Mary E.
    Noureddin, Mazen
    Harrison, Stephen A.
    HEPATOLOGY, 2020, 72 : 1029 - 1030
  • [8] Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
    Mudaliar, Sunder
    Henry, Robert R.
    Sanyal, Arun J.
    Morrow, Linda
    Marschall, Hanns-Ulrich
    Kipnes, Mark
    Adorini, Luciano
    Sciacca, Cathi I.
    Clopton, Paul
    Castelloe, Erin
    Dillon, Paul
    Pruzanski, Mark
    Shapiro, David
    GASTROENTEROLOGY, 2013, 145 (03) : 574 - +
  • [9] Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns
    Polyzos, Stergios A.
    Kountouras, Jannis
    Mantzoros, Christos S.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 104
  • [10] CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
    Pockros, Paul J.
    Fuchs, Michael
    Freilich, Bradley
    Schiff, Eugene
    Kohli, Anita
    Lawitz, Eric J.
    Hellstern, Paul A.
    Owens-Grillo, Janet
    Van Biene, Courtney
    Shringarpure, Reshma
    MacConell, Leigh
    Shapiro, David
    Cohen, David E.
    LIVER INTERNATIONAL, 2019, 39 (11) : 2082 - 2093
12345